StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Equities research analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Price Performance

Shares of NERV stock opened at $2.15 on Tuesday. The stock has a market cap of $15.03 million, a P/E ratio of -4.89 and a beta of 0.18. The company has a fifty day moving average price of $2.48 and a two-hundred day moving average price of $2.77. Minerva Neurosciences has a one year low of $2.07 and a one year high of $13.49.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.